These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3250450)

  • 21. Chemosensitivity testing predicts survival in ovarian cancer.
    Taylor CG; Sargent JM; Elgie AW; Williamson CJ; Lewandowicz GM; Chappatte O; Hill JG
    Eur J Gynaecol Oncol; 2001; 22(4):278-82. PubMed ID: 11695809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.
    Sevin BU; Perras JP
    Am J Obstet Gynecol; 1997 Apr; 176(4):759-66; discussion 766-8. PubMed ID: 9125599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
    Qian XL; Peng ZL; Liu SL
    Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination chemotherapy tested in a short-term thymidine incorporation assay in primary cultures of ovarian adenocarcinomas.
    Hayward IP; Hurst T; Parsons PG; Khoo SK
    Int J Cell Cloning; 1992 May; 10(3):182-9. PubMed ID: 1613269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay.
    Gerhardt RT; Perras JP; Sevin BU; Petru E; Ramos R; Guerra L; Averette HE
    Am J Obstet Gynecol; 1991 Aug; 165(2):245-55. PubMed ID: 1872324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
    Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
    Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin.
    Yu R; Jin H; Jin C; Huang X; Lin J; Teng Y
    Cell Biochem Funct; 2018 Mar; 36(2):80-87. PubMed ID: 29372560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [In vitro drug-resistance decrease of ovarian cancer cells].
    Lu SM
    Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):348-51, 383. PubMed ID: 2282862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer.
    Lewandowicz GM; Britt P; Elgie AW; Williamson CJ; Coley HM; Hall AG; Sargent JM
    Gynecol Oncol; 2002 May; 85(2):298-304. PubMed ID: 11972391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
    Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
    Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurement of tumor cell activity in short-term primary culture. Clinical significance in women with ovarian cancer.
    Khoo SK; Hurst T; Webb MJ; Dickie G; Kearsley J; Parsons PG; Mackay EV
    Cancer; 1988 Apr; 61(8):1579-86. PubMed ID: 3349421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines.
    Perez RP; Godwin AK; Handel LM; Hamilton TC
    Eur J Cancer; 1993; 29A(3):395-9. PubMed ID: 8398340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.
    Matassa DS; Amoroso MR; Lu H; Avolio R; Arzeni D; Procaccini C; Faicchia D; Maddalena F; Simeon V; Agliarulo I; Zanini E; Mazzoccoli C; Recchi C; Stronach E; Marone G; Gabra H; Matarese G; Landriscina M; Esposito F
    Cell Death Differ; 2016 Sep; 23(9):1542-54. PubMed ID: 27206315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemosensitivity testing of irinotecan (CPT-11) in ovarian and endometrial carcinomas: a comparison with cisplatin.
    Koshiyama M; Fujii H; Kinezaki M; Ohgi S; Konishi M; Hidetaka N; Hayashi M; Yoshida M
    Anticancer Res; 2000; 20(3A):1353-8. PubMed ID: 10928043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro chemosensitivity using the histoculture drug response assay in human epithelial ovarian cancer.
    Lee SW; Kim YM; Kim MB; Kim DY; Kim JH; Nam JH; Kim YT
    Acta Med Okayama; 2012; 66(3):271-7. PubMed ID: 22729108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
    Neubauer H; Stefanova M; Solomayer E; Meisner C; Zwirner M; Wallwiener D; Fehm T
    Anticancer Res; 2008; 28(2A):949-55. PubMed ID: 18507041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of cell proliferation and cell death based assays in chemosensitivity testing.
    Gerçel-Taylor C; Ackermann MA; Taylor DD
    Anticancer Res; 2001; 21(4A):2761-8. PubMed ID: 11724352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
    Kolfschoten GM; Hulscher TM; Pinedo HM; Boven E
    Br J Cancer; 2000 Oct; 83(7):921-7. PubMed ID: 10970695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.